Axiogenesis
| Axiogenesis AG | |
|---|---|
| legal form | Corporation |
| founding | 2001 |
| Seat | Cologne , Germany |
| Branch | biotechnology |
| Website | www.axiogenesis.com |
The Axiogenesis AG is a biotechnology company based in Cologne and provider of customized cell lines and applications of stem cell technology for pharmacology , toxicology , disease models and other purposes. The company was founded in 2001 and has been listed on the Frankfurt Stock Exchange since 2008. Axiogenesis has test methods for pharmacology as well as for safety screenings, especially in the pharmaceutical, chemical and cosmetic industries. These are based on embryonic stem cells (ESC) from mice, which are cultivated into differentiated tissues (e.g. heart, skin or liver) with normal physiological behavior.
In cooperation with the Fraunhofer Institute for Applied Information Technology to a method for fully automated was in vitro - cultivation operation and monitoring from tissue samples based on digital data and image processing systems ready for the market developed. On the basis of these tests, statements can be made about the effectiveness and toxicity of known and new substances. This procedure offers an alternative to animal testing .
The basic technology of almost all products and services from Axiogenesis is a patented process that solves one of the main problems in the “programming” of stem cells: the removal of the wrong cell types from the resulting cell mixture. B. only heart or liver cells are present. This method can be used on embryonic stem cells as well as on induced pluripotent stem cells . B. in the production of standardized or customized cell material for pharmacology, toxicology or disease models also concrete therapeutic perspectives. In mice after a heart attack, for example, the heart's pumping capacity could be significantly and permanently increased by transplanting stem cell-based heart cells.
history
- 2001: Foundation of Axiogenesis AG
- 2002: Development of a test system for pharmacological screenings for the development of heart drugs. For the first time, microelectrode arrays (MEA) are used to measure the effects of drugs on cardiomyocytes generated from embryonic stem cells.
- 2003: Development of the RETox system for checking the embryotoxicity of drugs and other chemicals.
- 2004: Development of a test system as an in vitro model for cardiomyopathy for the development of drugs against chronic heart failure. Successful transplantation of stem cell-based cardiomyocytes into heart attacked mice with permanent and significant improvement in pumping performance.
- 2005: Foundation of TÜV Biotec GmbH as a joint venture with the TÜV Rheinland Group and licensing of RETox to this company.
- 2006: Recognition of RETox as an equivalence procedure to other ESC tests by the European Center for the Validation of Alternative Methods (ECVAM)
- 2007: The Axiogenesis share is listed on the Frankfurt Stock Exchange
- 2009: Conclusion of an exclusive distribution agreement with Lonza AG for the distribution of stem cell-based cardiomyocytes
- 2010: License agreement with the iPS Academia Japan (Kyoto) for the use of the iPS technologies developed under the leadership of Professor Shinya Yamanaka
- 2017: Axiogenesis AG merges with the Belgian-Dutch Pluriomics BV to form Ncardia. The location in Cologne becomes Ncardia AG Germany.